Company news

Spyre Therapeutics, Inc. (NASDAQ:SYRE) news

Spyre Therapeutics, Inc. news releases on 6ix. Latest, Nov 11, 2024: Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results…

Spyre Therapeutics, Inc. (NASDAQ:SYRE) news

Press releases — page 2

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

Spyre Therapeutics to Participate in Upcoming Investor Conference

Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease

Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference

Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors

Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces $180 Million Private Placement

Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference

Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation

Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors

Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD

Aeglea BioTherapeutics Announces Grants of Inducement Awards

Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences

Aeglea BioTherapeutics to Participate in Upcoming September Conference

Aeglea BioTherapeutics Announces Reverse Stock Split

Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results

Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma

Aeglea BioTherapeutics Announces Grant of Inducement Awards

Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results

Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives

Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates

Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency

Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer

Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer

Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates

Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment

Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program

Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022

Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring

Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates

Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates

Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market

Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD

Aeglea BioTherapeutics to Participate in the Needham Virtual Healthcare Conferences in April 2022

Aeglea BioTherapeutics Announces Presentation of Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at the Society for Inherited Metabolic Disorders Annual Meeting

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates

Aeglea BioTherapeutics Withdraws Public Offering

Aeglea BioTherapeutics Announces Proposed Public Offering